Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors-Reference-Cited by-同舟云学术

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors

Published:2015-04-19 Issue:6 Volume:172 Page:1680-1682
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Vigarios E.¹²,Lamant L.³,Delord J.P.⁴,Fricain J.C.⁵⁶,Chevreau C.⁴,Barrés B.³,Gomez-Roca C.⁴,Boulanger M.¹²,Sibaud V.⁷

Affiliation:

1. Oral Oncology Department; Institut Claudius Regaud; Institut Universitaire du Cancer; Toulouse Oncopole; 1 av Irène Joliot-Curie 31059 Toulouse CEDEX 9 France

2. UFR Odontologie; 3 Chemin des Maraîchers 31062 Toulouse CEDEX 9 France

3. Pathology Department; Institut Claudius Regaud; Institut Universitaire du Cancer; Toulouse Oncopole; 1 av Irène Joliot-Curie 31059 Toulouse CEDEX 9 France

4. Oncology Department; Institut Claudius Regaud; Institut Universitaire du Cancer; Toulouse Oncopole; 1 av Irène Joliot-Curie 31059 Toulouse CEDEX 9 France

5. Oral Medicine Department; Pôle Odontologie et Santé Buccale; Hôpital Pellegrin; Place Amélie-Raba-Léon 33076 Bordeaux CEDEX France

6. UFR Odontologie Bordeaux; 16-20 Cours de la Marne 33076 Bordeaux CEDEX France

7. Dermatology Department; Institut Claudius Regaud; Institut Universitaire du Cancer; Toulouse Oncopole; 1 av Irène Joliot-Curie 31059 Toulouse CEDEX 9 France

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.13610/fullpdf

Reference10 articles.

1. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma;Anforth;Br J Dermatol,2012

2. Analysis of dermatologic events in vemurafenib-treated patients with melanoma;Lacouture;Oncologist,2013

3. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities;Sinha;Br J Dermatol,2012

4. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors;Oberholzer;J Clin Oncol,2012

5. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients;Boussemart;Ann Oncol,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy;Supportive Care in Cancer;2024-07-25

2. Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review;Healthcare;2024-01-02

3. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy;International Journal of Molecular Sciences;2023-05-03

4. New oral lesion by regorafenib: A case report;Oral Diseases;2022-04-19

5. Transplantation Medicine;Burket's Oral Medicine;2021-06-25